FRI0176 PHASE 2, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF A REVERSIBLE B CELL INHIBITOR, XMAB®5871, IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Merrill J, June J, Koumpouras F, Machua W, Khan M, Askanase A, Khosroshahi A, Sheikh S, James J, Guthridge J, Rathi G, Burington B, Foster P, Zack D. FRI0176 PHASE 2, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF A REVERSIBLE B CELL INHIBITOR, XMAB®5871, IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE). 2019, 761.2-762. DOI: 10.1136/annrheumdis-2019-eular.4234.Peer-Reviewed Original Research98 Results of a phase 2, double-blind, randomized, placebo-controlled study of a reversible B cell inhibitor, XmAb®5871, in systemic lupus erythematosus (SLE)
Merrill J, June J, Koumpouras F, Machua W, Khan M, Askanase A, Sheikh S, Khosroshahi A, Foster P, Zack D. 98 Results of a phase 2, double-blind, randomized, placebo-controlled study of a reversible B cell inhibitor, XmAb®5871, in systemic lupus erythematosus (SLE). 2019, a73-a74. DOI: 10.1136/lupus-2019-lsm.98.Peer-Reviewed Original Research